VivoSeq
Other

Chimeric Antigen Receptor T-Cell

0

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

Chimeric Antigen Receptor T-cell is an early-stage landscape with 0 programs across 2 companies. The most active players are Bioceltech Therapeutics, Ltd., Celyad Oncology SA.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Bioceltech Therapeutics, Ltd.

0 programs

PreclinicalC

Celyad Oncology SA

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Unknown status3 · 43%
Active, not recruiting2 · 29%
Recruiting2 · 29%

Clinical Trials

Trial Activity

7 trials

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
Recruiting·UUniversity of Colorado, Denver·Phase 1·NCT06559189·53 enrolled
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
Recruiting·CCelyad Oncology SA·Phase 1·NCT03692429·49 enrolled
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Active, not recruiting·WWashington University School of Medicine·Phase 1·NCT05044039·42 enrolled
Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen
Active, not recruiting·—·Phase 1·NCT04219163·18 enrolled
Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL
Unknown status·BBioceltech Therapeutics, Ltd.·Phase 1·NCT05554575·15 enrolled
A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies
Unknown status·SShandong University·Phase 1·NCT04011293·20 enrolled
A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell (CART) in the Treatment of Solid Tumors
Unknown status·—·N/A·NCT05745454·12 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)